Blood-based biomarkers for immune-based therapy in advanced HCC: Promising but a long way to go

Blood-based biomarkers for immune-based therapy in advanced HCC: Promising but a long way to go

The introduction of immune checkpoint inhibitors (ICIs) represents a key shift in the management strategy for patients with hepatocellular carcinoma (HCC). However, there is a paucity of predictive biomarkers that facilitate the identification of patients that would respond to ICI therapy. Although...

Full description

Bibliographic Details
Main Authors: Pil Soo Sung, Isaac Kise Lee, Pu Reun Roh, Min Woo Kang, Jaegyoon Ahn, Seung Kew Yoon
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-10-01
Series:Frontiers in Oncology
Subjects:
hepatocellular carcinoma
immune checkpoint inhibitors
biomarker
circulating tumor DNA
patient outcomes
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2022.1028728/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2022.1028728/full

Similar Items